Literature DB >> 19340392

A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease.

Walter Maetzler1, Joan Michelis, Juergen Tomiuk, Arthur Melms, Clemens Becker, Thomas Gasser, Claudia Schulte, Daniela Berg.   

Abstract

In Lewy body disease, inflammation is discussed to be involved in the pathophysiological cascade. Osteopontin (OPN) is a multifunctional molecule, which is increased in inflammatory states. Here, we analyzed the allele frequency of two SNPs of the OPN gene, serum, and CSF OPN levels in Lewy body disease patients and controls. In accordance with our previous findings, we detected increased serum (P = 0.006) and CSF OPN levels (P = 0.0003) in the Lewy body disease cohort, compared to non-Lewy body disease subjects. The genotypic variation of SNP-66 was associated with the occurrence of Lewy body disease (odds ratio: 2.64, 95% CI 1.07-6.54, unadjusted P = 0.036). SNP+1239 was not related to Lewy body disease prevalence (odds ratio 1.61, 95% CI 0.66-3.91, P = 0.29). Genotype prevalence and OPN levels were not significantly related. These findings suggest that OPN is associated with the occurrence of Lewy body disease and SNP-66 may be a susceptibility factor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340392     DOI: 10.1007/s00702-009-0209-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  38 in total

1.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

Authors:  Ashley D Reynolds; Rebecca Banerjee; Jianou Liu; Howard E Gendelman; R Lee Mosley
Journal:  J Leukoc Biol       Date:  2007-08-03       Impact factor: 4.962

2.  Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.

Authors:  R Zohar; N Suzuki; K Suzuki; P Arora; M Glogauer; C A McCulloch; J Sodek
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

Review 3.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

4.  Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses.

Authors:  K Wakabayashi; H Takahashi; S Takeda; E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Osteopontin prevents monocyte recirculation and apoptosis.

Authors:  Tricia H Burdo; Malcolm R Wood; Howard S Fox
Journal:  J Leukoc Biol       Date:  2007-03-16       Impact factor: 4.962

7.  Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients.

Authors:  L Migliore; L Petrozzi; C Lucetti; G Gambaccini; S Bernardini; R Scarpato; F Trippi; R Barale; G Frenzilli; V Rodilla; U Bonuccelli
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

8.  Eta-1/osteopontin genetic polymorphism and primary biliary cirrhosis.

Authors:  Kentaro Kikuchi; Atsushi Tanaka; Hiroshi Miyakawa; Yumi Kawashima; Naomi Kawaguchi; Masanao Matsushita; M Eric Gershwin
Journal:  Hepatol Res       Date:  2003-06       Impact factor: 4.288

9.  Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat.

Authors:  Joanna Iczkiewicz; Sarah Rose; Peter Jenner
Journal:  Eur J Neurosci       Date:  2005-04       Impact factor: 3.386

10.  High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation.

Authors:  Annalisa Chiocchetti; Manuela Indelicato; Thea Bensi; Riccardo Mesturini; Mara Giordano; Selina Sametti; Luca Castelli; Flavia Bottarel; Maria Clorinda Mazzarino; Letizia Garbarini; Francesca Giacopelli; Guido Valesini; Claudio Santoro; Irma Dianzani; Ugo Ramenghi; Umberto Dianzani
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

View more
  5 in total

1.  Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice.

Authors:  Walter Maetzler; Daniela Berg; Claudia Funke; Freya Sandmann; Holger Stünitz; Corina Maetzler; Cordula Nitsch
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

Review 2.  Predicting cognitive decline in Parkinson's disease: can we ask the genes?

Authors:  Fabiola De Marchi; Miryam Carecchio; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2014-10-27       Impact factor: 4.003

Review 3.  The Yin-Yang of osteopontin in nervous system diseases: damage versus repair.

Authors:  Giuseppe Cappellano; Domizia Vecchio; Luca Magistrelli; Nausicaa Clemente; Davide Raineri; Camilla Barbero Mazzucca; Eleonora Virgilio; Umberto Dianzani; Annalisa Chiocchetti; Cristoforo Comi
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

4.  Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease.

Authors:  Yuan Sun; Xue Song Yin; Hong Guo; Rong Kun Han; Rui Dong He; Li Jun Chi
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

5.  Genome-wide epigenetic analyses in Japanese immigrant plantation workers with Parkinson's disease and exposure to organochlorines reveal possible involvement of glial genes and pathways involved in neurotoxicity.

Authors:  Rodney C P Go; Michael J Corley; G Webster Ross; Helen Petrovitch; Kamal H Masaki; Alika K Maunakea; Qimei He; Maarit I Tiirikainen
Journal:  BMC Neurosci       Date:  2020-07-10       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.